Global Biotech M&A Deal Tracker 2023–2025: Global Exits & Acquisitions

The definitive, investment-grade analysis of global biotechnology M&A activity from 2023–2025. Features exclusively primary-sourced deal data, advanced sector analysis, and actionable insights for corporate, investor, and advisory clients.

Overview

Gain unrivaled strategic insight into the biotechnology M&A landscape with the Biotech M&A Deal Tracker 2023–2025: Global Exits & Acquisitions. This report provides a comprehensive, audit-ready analysis of major exits, acquisitions, and sector trends from January 2023 to July 2025, compiled exclusively from Tier 1 and Tier 2 primary sources (SEC filings, company press releases, investor presentations, audited statements).

What Sets This Report Apart

  • 100% Primary Sourcing: Every datapoint is directly sourced and verifiable. No speculative models or black-box data.
  • Strategic Curation: Only the most impactful transactions and market trends—no data dumps, only actionable insight.
  • Advanced Benchmarking: Valuation multiples, deal premiums, and stage/modality analyses across >25 major deals.
  • Actionable Frameworks: Tactical guidance for acquirers and sellers, regulatory scenario modeling, and real-world case studies.
  • Audit Trail: Full appendix with clickable source links for due diligence.

Key Content & Deliverables

  • Executive summary of 2023–2025 M&A market trends and sector outlook
  • Master tables of major biotech deals ($500M+), with deal value, therapeutic focus, buyer/target, and source
  • In-depth analysis of sector focus (oncology, immunology, neuroscience, rare disease, cardiometabolic, etc.)
  • Quantitative benchmarking: acquisition premiums by stage, deal multiples, modality “gold rush” analysis
  • Regional and cross-border M&A trends (APAC/China, EU, US)
  • Scenario analysis for 2026–2027, including IRA/regulatory headwinds and capital market outlook
  • Case studies (Pfizer/Seagen, BMS/Karuna, AstraZeneca/Gracell, etc.)
  • Strategic frameworks for BD teams, boards, and advisors (IRA durability, FTC profiling, asset vs. platform M&A)
  • Full audit trail with primary sources listed

Who Should Buy This Report?

  • Pharma & Biotech Executives: Corporate strategy, BD/M&A, portfolio management
  • Private Equity, VC, and Investors: Deal origination, benchmarking, due diligence
  • Consultants & Advisors: Client delivery, valuation, regulatory/competitive strategy
  • Legal, Compliance & Audit: Source-verifiable, regulatory-grade data for high-stakes decisions

 

35+ pages of analysis, charts, and reference tables and includes full appendix with sources and methodology


Key Features / Bullets

  • Exclusive primary-source data—no third-party or speculative figures
  • Covers all $500M+ global biotech M&A transactions (2023–2025)
  • Therapeutic area analysis: Oncology, immunology, neuroscience, rare disease, cardiometabolic
  • Advanced deal benchmarking: Premiums, multiples, modality trends
  • Scenario planning for 2026–2027 (regulatory, IRA, capital markets)
  • Strategic frameworks for M&A teams
  • Full source audit trail for due diligence
  • License and confirmation immediate upon purchase with the report delivered within 24 hours.

Table Of Contents

  • Methodology & Differentiators: Why This Report is Investment-Grade
  • Executive Summary
  • Forward-Looking Outlook (2026-2027)
  • Investment & Funding Landscape: M&A Market Dynamics
  • M&A Focus by Therapeutic Area (2023-2025)
  • Investment & Funding Landscape: Major M&A Transactions (2023 3 2025)
  • Key Biotechnology M&A Transactions (2023 3 H1 2025) – Part 2
  • Key Biotechnology M&A Transactions (2023 3 H1 2025) – Part 3
  • Beyond the Headlines: SMID-Cap, Private, and Regional Deal Flow
  • Advanced Analysis: Deal Multiples & Valuation Environment
  • Advanced Quantitative Benchmarking: Valuation & Deal Structures
  • M&A Landscape by Value, Stage, and Modality (2023-2025)
  • Regional Deep Dive: APAC & Cross-Border Dynamics
  • Cross-Border Case Study: AstraZeneca Acquires Gracell Biotechnologies ($1.2B)
  • Actionable Intelligence & Tactical Frameworks
  • Scenario Analysis: Potential M&A Headwinds & Tailwinds (2026-2027)
  • R&D Pipeline & Regulatory Context
  • Case Study: Bristol Myers Squibb Acquires Karuna Therapeutics ($14B)
  • Competitive & Strategic Landscape
  • The Rise of “Bolt-on” Acquisitions
  • Modality Mania: The ADC Gold Rush
  • Regional Dynamics
  • Commercialization & Financial Outlook
  • Forward-Looking Commentary: 2026-2027 Projections & Analysis
  • Forward-Looking Commentary: IRA-Driven Portfolio Shaping
  • Forward-Looking Commentary: Additional Trends
  • Audit Trail & Sources Appendix
  • Sources Appendix

Price range: $ 1,299.00 through $ 1,699.00

  • Primary Source-Driven, Fully Auditable Intelligence

    All reported content is based strictly on Tier 1–2 sources: regulatory filings (SEC, SEDAR, HKEX), official stock exchange data, regulatory approvals (FDA, EMA), company press releases, and Big Four or investment bank research. Every data point and table is directly sourced, with retrieval dates and audit trails. Reports include a detailed sources appendix, listing every document, retrieval date, and access method—ensuring auditability and trust for compliance and institutional use.

  • Comprehensive, Multi-Layered Market Analysis

    Each report covers the entire innovation and funding lifecycle—market sizing, capital flows, IPOs, M&A, licensing, and R&D pipeline—with in-depth analyses of region, modality, and company strategy—no estimates from third-party research firms; only verified, official disclosures. Comprehensive tables detail fundraising rounds, IPOs, licensing deals, and acquisitions—with columns for company, amount, date, investors, region, R&D focus, and source link—facilitating quick benchmarking and due diligence.

  • Structured for C-Suite, Investors & Domain Experts

    Reports are written for institutional and sophisticated audiences, using sector-appropriate terminology and frameworks. Includes clear executive summary, methodology, tables, risk matrix, and actionable insights. Insightful projections for upcoming years are included—always grounded in present data and macro trends, never speculative. Scenario analysis and risk matrices help inform strategy and risk management.

  • Quantitative Rigor & Data Integrity

    Only actual, verifiable numbers are used. All financial data is standardized to USD, with reporting standards (IFRS/GAAP) and fiscal year notes included. Claims are cross-validated across multiple source tiers where possible.

  • In-Depth R&D, Clinical & Regulatory Analysis

    Detailed mapping of lead programs, clinical progress, regulatory milestones, and commercialization status—sourced from filings, trial registries, and agency releases. Highlights key scientific differentiators and competitive positions.

Frequently Asked Questions

How is the data sourced, and how do you ensure its accuracy and reliability?

All data is sourced exclusively from primary, auditable sources—such as regulatory filings (e.g., SEC, SEDAR, HKEX), official stock exchange data, company press releases, investor presentations, and regulatory agency announcements (FDA, EMA, etc.). We never use unverifiable third-party estimates or market research reports. Every key figure is cross-checked across multiple Tier 1–2 sources and documented with direct links and retrieval dates. A full audit trail is provided in each report’s appendix for complete transparency.

How frequently is the data updated, considering different financial years and reporting timelines across countries?

Industry Informant Inc. is committed to delivering timely and accurate data. For countries with higher demand, we update our biotech intelligence data on a quarterly basis. We ensure updates at least once a year for other regions, especially where data acquisition might be challenging. This approach provides our clients can access the most recent and relevant information, irrespective of the country of interest.

How comprehensive is the coverage, and does it include all significant companies and emerging players in the sector?

Our reports strive for comprehensive coverage of all significant public companies and major private firms, with a focus on those driving sector innovation, funding, and clinical progress. We prioritize firms that disclose through official regulatory channels and make efforts to include key emerging players where reliable data is available. Each report specifies inclusion/exclusion criteria and data limitations, if any.

How is the price of each Biotech Intelligence Report determined?

Pricing reflects the depth of research, the rigor of data sourcing, and the value delivered to institutional clients. Reports are priced based on the volume of original analysis, breadth of primary-source data, and actionable strategic insights included. Each purchase grants you access to a premium, fully auditable market intelligence asset designed for professional decision-makers.

Is the data suitable for compliance, due diligence, and investment decision-making?

Absolutely. All analysis is grounded in Tier 1 and Tier 2 sources with direct audit trails, making it suitable for use in compliance, regulatory submissions, corporate due diligence, and institutional investment decisions. Our methodology and sourcing exceed the standards expected by C-suite, legal, and audit teams.

How does Industry Informant Inc. handle currency conversion and reporting standard differences?

All financial data is standardized to USD using official exchange rates as of the reporting date. Differences in reporting standards (e.g., IFRS vs. GAAP) and fiscal years are clearly noted within each report and in all relevant tables.

What is your refund policy for the Biotech Intelligence Data I purchase?

Conditional Refund Policy

At Industry Informant Inc., we are committed to customer satisfaction and transparency. Given the irrevocable nature of digital market intelligence products, refunds are provided only in clearly defined situations, as outlined below:

  • Partial Refunds: If you experience a technical failure in accessing your purchased data or can demonstrate material inaccuracies that affect the report’s substantive value, you may be eligible for a partial refund of up to 50% of the purchase price. The specific amount will be determined after internal review of the issue.

  • Correction or Replacement First: Industry Informant Inc. reserves the right to attempt to correct or replace the product before considering any refund.

  • Refund Request Window: All refund requests must be submitted within seven (7) days of the purchase date. Requests received after this window cannot be considered.

  • Proof Required: To process a refund, customers must provide clear, documented evidence of the technical issue or material inaccuracy (e.g., screenshots, error messages, or specific data errors) to support their claim.

  • Significant Inaccuracies Defined: Only errors that materially impact the utility, validity, or completeness of the report/data are eligible; minor typographical errors or formatting issues do not qualify.

  • No Refunds for Change of Mind: Refunds are not available for changes of mind, or if the data no longer meets a need due to external circumstances.

  • One Refund Per Product: Each customer is entitled to one refund request per product. Repeat refund requests for the same purchase will not be entertained.

  • Processing Time: Approved refunds will be processed within ten (10) business days of confirmation.

  • Final Decision: All refund decisions are at the sole discretion of Industry Informant Inc. we aim to be fair and reasonable in all cases.

By purchasing our market intelligence products, you agree to these terms. Please do not hesitate to contact us with any questions or concerns.

Ready to Transform Your Business Strategy?

Explore our ever growing library of upcoming and completed market research projects. Feel free to contact us to learn more about our market research reports. Our team is ready to answer any questions you may have.